IN2014DN08158A - - Google Patents

Info

Publication number
IN2014DN08158A
IN2014DN08158A IN8158DEN2014A IN2014DN08158A IN 2014DN08158 A IN2014DN08158 A IN 2014DN08158A IN 8158DEN2014 A IN8158DEN2014 A IN 8158DEN2014A IN 2014DN08158 A IN2014DN08158 A IN 2014DN08158A
Authority
IN
India
Prior art keywords
disclosed
methods
function
specific inhibitor
smad7 expression
Prior art date
Application number
Inventor
Giovanni Monteleone
Peter Buchwald
Luca Inverardi
Antonello Pileggi
Camillo Ricordi
Alice Tomei
Original Assignee
Nogra Pharma Ltd
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd, Univ Miami filed Critical Nogra Pharma Ltd
Publication of IN2014DN08158A publication Critical patent/IN2014DN08158A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Abstract

Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell e.g. pancreatic islet cell survival after transplantation using a specific inhibitor of SMAD7 expression or function.
IN8158DEN2014 2012-04-18 2013-04-18 IN2014DN08158A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261625904P 2012-04-18 2012-04-18
PCT/US2013/037150 WO2013158868A1 (en) 2012-04-18 2013-04-18 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation

Publications (1)

Publication Number Publication Date
IN2014DN08158A true IN2014DN08158A (en) 2015-05-01

Family

ID=48326412

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8158DEN2014 IN2014DN08158A (en) 2012-04-18 2013-04-18

Country Status (15)

Country Link
US (3) US10081809B2 (en)
EP (1) EP2839004B1 (en)
JP (2) JP6348484B2 (en)
KR (1) KR20150003824A (en)
CN (2) CN107252492A (en)
AU (1) AU2013249191B2 (en)
CA (1) CA2870547A1 (en)
DK (1) DK2839004T3 (en)
ES (1) ES2732252T3 (en)
HK (1) HK1207117A1 (en)
IN (1) IN2014DN08158A (en)
MX (1) MX370149B (en)
NZ (1) NZ630914A (en)
RU (1) RU2667960C2 (en)
WO (1) WO2013158868A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
CA2743329C (en) 2008-11-13 2020-09-01 Giuliani International Limited Antisense compositions and methods of making and using same
CN104040349B (en) 2011-09-15 2017-07-04 诺格尔制药有限公司 Reactive method for monitoring confrontation SMAD7 therapies
JP6348484B2 (en) 2012-04-18 2018-06-27 ノグラ ファーマ リミテッド Methods for treating diabetes and / or promoting islet survival after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
EP2940115B1 (en) * 2014-04-30 2018-10-17 The Procter and Gamble Company Cleaning composition
MA39963A (en) 2014-05-09 2017-03-15 Nogra Pharma Ltd Methods for treating inflammatory bowel disease
CN107406851A (en) 2014-10-17 2017-11-28 诺格尔制药有限公司 Utilize the method and composition of SMAD7 antisense strategy subjects
EP3162878A1 (en) * 2015-10-29 2017-05-03 The Procter and Gamble Company Liquid detergent composition
ES2718380T3 (en) * 2015-10-29 2019-07-01 Procter & Gamble Liquid detergent composition
JP2019505598A (en) 2016-02-23 2019-02-28 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Method of treating intestinal fibrosis using inhibition of SMAD7
WO2019217571A1 (en) * 2018-05-08 2019-11-14 University Of Miami Materials and methods for the delivery of therapeutic nucleic acids to tissues
KR102503349B1 (en) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 Methods and compositions for preventing type 1 diabetes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
ATE554169T1 (en) * 2001-11-02 2012-05-15 Giuliani Int Ltd SMAD7 INHIBITORS FOR THE TREATMENT OF CNS DISEASES
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
DK3604537T3 (en) 2003-06-13 2022-02-28 Alnylam Europe Ag Double-stranded ribonucleic acid with increased efficiency in an organism
ITRM20030393A1 (en) * 2003-08-11 2005-02-12 Giuliani Spa USE OF OLIGONUCLEOTIDES (ODN) ANTISENSE FOR SMAD7 FOR THE TREATMENT OF PATHOLOGIES MEDIATED BY NUCLEAR TRANSFER FACTOR NF-KB.
GB0326778D0 (en) 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
RU2434942C2 (en) * 2004-09-28 2011-11-27 Кварк Фармасьютикалс, Инк. Oligiribonucleotides and methods of their application for treatment of acute renal failure and other diseases
NZ553987A (en) 2004-09-28 2011-01-28 Quark Pharmaceuticals Inc Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
WO2007039151A1 (en) 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
EP2982753B1 (en) 2008-04-18 2018-06-06 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
CA2743329C (en) 2008-11-13 2020-09-01 Giuliani International Limited Antisense compositions and methods of making and using same
CN104040349B (en) 2011-09-15 2017-07-04 诺格尔制药有限公司 Reactive method for monitoring confrontation SMAD7 therapies
JP6348484B2 (en) 2012-04-18 2018-06-27 ノグラ ファーマ リミテッド Methods for treating diabetes and / or promoting islet survival after transplantation
ES2673209T3 (en) 2013-03-15 2018-06-20 Nogra Pharma Limited Colorectal Cancer Treatment Procedures
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
MA39963A (en) 2014-05-09 2017-03-15 Nogra Pharma Ltd Methods for treating inflammatory bowel disease
CN107406851A (en) 2014-10-17 2017-11-28 诺格尔制药有限公司 Utilize the method and composition of SMAD7 antisense strategy subjects
CA2964673A1 (en) 2014-10-17 2016-04-21 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
EP3355896A2 (en) 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
JP2019507755A (en) 2016-02-24 2019-03-22 ノグラ ファーマ リミテッド Methods of treating celiac disease using SMAD7 inhibition
WO2018122376A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Also Published As

Publication number Publication date
US20150315573A1 (en) 2015-11-05
CN107252492A (en) 2017-10-17
US20200239884A1 (en) 2020-07-30
NZ630914A (en) 2017-01-27
HK1207117A1 (en) 2016-01-22
MX2014012650A (en) 2015-04-08
CN104487574B (en) 2017-07-07
US20190136237A1 (en) 2019-05-09
DK2839004T3 (en) 2019-07-01
RU2014146170A (en) 2016-06-10
CA2870547A1 (en) 2013-10-24
JP2015514778A (en) 2015-05-21
EP2839004A1 (en) 2015-02-25
AU2013249191B2 (en) 2019-01-03
WO2013158868A1 (en) 2013-10-24
ES2732252T3 (en) 2019-11-21
EP2839004B1 (en) 2019-06-12
JP2018131468A (en) 2018-08-23
US10081809B2 (en) 2018-09-25
KR20150003824A (en) 2015-01-09
JP6348484B2 (en) 2018-06-27
CN104487574A (en) 2015-04-01
MX370149B (en) 2019-12-03
AU2013249191A1 (en) 2014-10-09
RU2667960C2 (en) 2018-09-25
US10443056B2 (en) 2019-10-15

Similar Documents

Publication Publication Date Title
IN2014DN08158A (en)
PH12019502292A1 (en) Methods and compositions for treatment of a genetic condition
MX2015013154A (en) Use of perfusion decellularized liver for islet cell recellularization.
GB0920703D0 (en) Compositions containing satiogens and methods of use
MX355728B (en) Kinase inhibitors.
PH12014502588A1 (en) Catechol o-methyltransferase activity inhibiting compounds
PH12014500995A1 (en) Pak inhibitors for the treatment of cell proliferative disorders
IL224451A (en) Method of producing pancreatic hormone-producing cells
IL221481A0 (en) Method of efficiently establishing induced pluripotent stem cells
MX371176B (en) Hollow fiber cartridges and components and methods of their construction.
MX2014013752A (en) Nampt inhibitors.
IL262554A (en) Purification method for pancreatic precursor cells derived from pluripotent stem cells and amplification method therefor
MX348311B (en) Nampt inhibitors.
HK1218430A1 (en) Method of treating pancreatic and liver conditions by transplantation of stem cells into bile duct walls
UA111475C2 (en) Method of treatment using lipid substances
MX337486B (en) Controlled degradation fibers.
EP2635678A4 (en) Method of efficiently establishing induced pluripotent stem cells
MX2021000332A (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor.
EP2616540A4 (en) Method of efficiently establishing induced pluripotent stem cells
SG11201408717XA (en) Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus
IL213629A0 (en) Apparatus and method for the preservation of pancreatic tissue and islet cells for transplantation
MX2010007945A (en) Pancreatic islet cell preparation and transplantation.
MX2015007608A (en) Methods and compositions for inhibiting cnksr1.
IN2014CN02585A (en)
AU335165S (en) Analogue clock